ZIOPHARM Oncology (ZIOP) stock price, revenue, and financials

ZIOPHARM Oncology market cap is $647.1 m, and annual revenue was $146 k in FY 2018

$647.1 M

ZIOP Mkt cap, 16-Sept-2020
ZIOPHARM Oncology Net income (Q2, 2020)-18.6 M
ZIOPHARM Oncology EBIT (Q2, 2020)-18.6 M
ZIOPHARM Oncology Cash, 30-Jun-2020153.5 M
ZIOPHARM Oncology EV494.8 M

ZIOPHARM Oncology Income Statement

ZIOPHARM Oncology Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

104.7m73.3m68.2m42.8m140.7m81.1m70.9m61.7m

Accounts Receivable

79.0k58.0k145.0k145.0k446.0k508.4m19.0k1.9m

Prepaid Expenses

1.3m6.9m1.9m1.1m11.4m19.8m20.7m

Inventories

23.8m

Current Assets

106.1m80.3m70.3m44.1m152.5m104.9m90.8m84.3m

PP&E

1.1m2.0m801.0k531.0k581.0k843.0k1.2m1.1m

Total Assets

108.1m83.4m71.8m45.2m153.7m106.3m105.6m95.1m

Accounts Payable

1.7m1.5m422.0k2.0m2.0m156.0k4.4m707.0k

Short-term debt

Current Liabilities

13.4m18.9m7.8m10.8m18.1m15.8m20.9m9.5m

Long-term debt

Total Debt

Total Liabilities

36.5m35.0m22.4m11.4m66.4m58.3m58.4m9.5m

Common Stock

69.0k83.0k100.0k104.0k132.0k143.0k161.0k

Preferred Stock

Additional Paid-in Capital

246.5m325.2m386.5m406.3m579.9m615.5m651.7m

Retained Earnings

(283.7m)(372.6m)(492.7m)(658.0m)(712.4m)(566.3m)

Total Equity

71.6m48.4m49.4m33.8m87.4m(77.3m)(96.8m)85.6m

Financial Leverage

1.5 x1.7 x1.5 x1.3 x1.8 x-1.4 x-1.1 x1.1 x

Quarterly

USDQ3, 2010Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

66.5m130.3m118.9m128.0m110.4m95.3m55.7m38.9m23.6m60.4m53.0m46.1m129.7m118.6m163.8m124.8m109.0m94.7m66.4m97.2m84.4m51.1m40.4m31.7m51.5m43.6m88.4m171.0m153.5m

Accounts Receivable

79.0k13.0k72.0k31.0k449.0k27.0k32.0k208.0k62.0k89.0k369.0k1.1m15.0k25.0k67.0k44.0k13.0k18.0k663.0k1.0m854.0k1.5m3.4m782.0k4.1m

Prepaid Expenses

352.0k1.0m1.4m10.8m9.1m7.2m4.8m4.1m3.2m1.6m991.0k1.5m857.0k4.4m8.3m14.5m17.7m21.0m26.2m27.9m30.5m21.0m11.9m14.4m21.8m20.8m23.7m19.8m15.6m

Current Assets

66.8m131.3m120.4m138.8m119.4m102.6m60.6m43.0m27.3m62.0m54.0m47.8m130.6m123.1m172.5m140.4m126.7m115.7m92.8m125.1m114.9m72.1m53.0m47.2m74.1m65.9m115.6m191.6m173.2m

PP&E

230.0k549.0k886.0k1.2m2.0m2.1m1.9m1.7m1.3m679.0k683.0k654.0k426.0k321.0k262.0k667.0k682.0k825.0k1.1m1.1m1.0m1.2m1.3m1.3m967.0k877.0k828.0k3.8m5.7m

Total Assets

67.5m132.8m122.3m140.9m122.4m105.6m63.3m45.6m29.5m63.3m55.3m49.1m131.6m124.0m173.4m141.7m128.0m117.1m94.5m126.8m116.6m87.5m76.4m66.8m83.5m73.2m117.9m198.3m181.7m

Accounts Payable

1.1m1.8m2.2m2.0m1.5m4.2m983.0k1.2m891.0k578.0k447.0k2.0m779.0k3.1m4.2m1.9m2.0m1.8m226.0k81.0k1.5m606.0k588.0k1.3m859.0k941.0k926.0k396.0k1.1m

Current Liabilities

4.1m8.7m11.8m14.3m17.8m21.7m20.4m21.0m13.4m7.4m10.8m11.7m10.5m13.1m29.6m17.3m16.0m15.7m17.5m16.0m18.2m10.1m9.3m60.2m8.3m10.4m11.2m16.6m17.1m

Long-term debt

948.0k778.0k647.0k1.4m1.2m

Total Debt

948.0k778.0k647.0k1.4m1.2m

Total Liabilities

25.2m48.7m38.2m43.2m46.7m46.6m25.5m26.3m25.8m21.6m17.6m12.6m11.0m13.6m79.5m63.9m180.0m59.7m60.0m56.9m57.3m61.6m61.2m62.8m9.3m11.2m11.8m17.9m18.3m

Common Stock

49.0k68.0k68.0k80.0k80.0k80.0k84.0k84.0k84.0k101.0k101.0k103.0k128.0k131.0k131.0k132.0k132.0k132.0k132.0k142.0k142.0k142.0k142.0k142.0k162.0k162.0k181.0k214.0k214.0k

Preferred Stock

Additional Paid-in Capital

131.3m243.8m244.7m302.6m304.2m305.5m327.5m330.7m331.8m388.6m390.2m398.6m571.3m575.4m576.9m582.4m583.8m582.2m578.6m622.1m619.2m613.3m609.2m604.7m653.8m656.2m774.3m882.5m884.2m

Retained Earnings

235.7m(356.1m)(362.2m)(450.8m)(465.1m)(483.2m)(504.7m)(635.9m)(646.8m)(673.6m)(686.5m)(699.2m)(736.6m)(748.6m)(761.2m)(579.8m)(594.4m)(668.4m)(702.4m)(721.0m)

Total Equity

42.2m84.1m84.1m97.7m75.6m59.0m37.9m19.3m3.6m41.7m37.7m36.5m120.6m110.4m93.8m77.8m(52.0m)(64.4m)(94.9m)(64.3m)(79.8m)(123.1m)(139.2m)(156.4m)74.2m62.0m106.1m180.3m163.4m

Financial Leverage

1.6 x1.6 x1.5 x1.4 x1.6 x1.8 x1.7 x2.4 x8.1 x1.5 x1.5 x1.3 x1.1 x1.1 x1.8 x1.8 x-2.5 x-1.8 x-1 x-2 x-1.5 x-0.7 x-0.5 x-0.4 x1.1 x1.2 x1.1 x1.1 x1.1 x

ZIOPHARM Oncology Cash Flow

Quarterly

USDQ3, 2010Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(20.8m)(49.7m)(50.5m)(24.5m)(48.1m)(65.9m)(12.8m)(31.5m)(48.2m)(9.7m)(15.3m)(21.4m)(78.2m)(92.4m)(110.6m)(12.0m)(143.2m)(154.1m)(15.5m)(28.3m)(41.0m)(16.0m)(28.1m)(40.6m)(13.4m)(28.1m)(102.0m)(18.3m)(36.9m)

Depreciation and Amortization

153.0k95.0k172.0k118.0k265.0k466.0k199.0k396.0k582.0k124.0k217.0k339.0k122.0k236.0k295.0k72.0k155.0k227.0k79.0k167.0k259.0k117.0k255.0k412.0k140.0k296.0k453.0k142.0k390.0k

Accounts Receivable

(79.0k)79.0k79.0k(66.0k)(14.0k)27.0k(391.0k)118.0k113.0k(63.0k)83.0k55.0k(224.0k)(614.0k)431.0k421.0k(46.0k)(23.0k)8.0k1.0k(645.0k)(1.0m)1.0m404.0k(1.6m)2.5m(742.0k)

Accounts Payable

(703.0k)753.0k1.1m257.0k(258.0k)2.5m(526.0k)(344.0k)(618.0k)156.0k25.0k1.5m(1.2m)1.1m2.2m(100.0k)23.0k(194.0k)70.0k(75.0k)1.4m(3.8m)(3.8m)(3.1m)152.0k234.0k219.0k(510.0k)176.0k

Cash From Operating Activities

(13.9m)(14.0m)(25.1m)(25.9m)(42.6m)(57.3m)(18.2m)(35.0m)(50.5m)(8.7m)(16.3m)(26.8m)(9.7m)(21.4m)23.8m(16.1m)(31.2m)(45.3m)(14.3m)(29.8m)(42.5m)(19.0m)(29.1m)(37.6m)(10.2m)(18.3m)(29.2m)(9.9m)(23.9m)

Purchases of PP&E

(128.0k)(392.0k)(806.0k)(154.0k)(1.1m)(1.5m)(114.0k)(115.0k)(119.0k)(2.0k)(99.0k)(193.0k)(17.0k)(22.0k)(25.0k)(157.0k)(257.0k)(469.0k)(358.0k)(385.0k)(461.0k)(150.0k)(376.0k)(545.0k)(10.0k)(77.0k)(184.0k)(513.0k)(4.0m)

Cash From Investing Activities

(128.0k)(392.0k)(806.0k)(154.0k)(1.1m)(1.5m)(114.0k)(115.0k)(118.0k)(2.0k)(99.0k)(193.0k)(17.0k)(22.0k)(25.0k)(157.0k)(257.0k)(469.0k)(358.0k)(385.0k)(461.0k)(150.0k)(376.0k)(545.0k)(10.0k)(77.0k)(184.0k)(513.0k)(4.0m)

Cash From Financing Activities

31.7m84.3m84.4m49.3m49.4m49.4m706.0k705.0k907.0k837.0k1.2m4.9m96.6m97.2m97.3m365.0k(304.0k)(304.0k)29.0k46.3m46.3m(731.0k)(1.0m)(1.0m)230.0k56.1m101.7m101.7m

Net Change in Cash

17.6m69.9m58.5m23.3m5.7m(9.4m)(17.7m)(34.4m)(49.7m)(7.8m)(15.2m)(22.1m)86.9m75.7m121.0m(15.9m)(31.7m)(46.0m)(14.6m)16.1m3.4m(19.8m)(30.5m)(39.2m)(10.2m)(18.2m)26.7m91.3m73.8m

Interest Paid

Income Taxes Paid

ZIOPHARM Oncology Ratios

USDQ3, 2010

Financial Leverage

1.6 x